| Total population | Females | Males |
---|
Glucosamine non-users | Glucosamine users | Glucosamine non-users | Glucosamine users | Glucosamine non-users | Glucosamine users |
---|
Total | 352,476 | 84,118 | 188,576 | 53,433 | 163,900 | 30,685 |
No of events | 6156 | 1247 | 1375 | 343 | 4781 | 904 |
Incidence rates* | 1.5 | 1.3 | 0.6 | 0.5 | 2.5 | 2.5 |
Crude model | ref | 0.84(0.79, 0.90) | ref | 0.88(0.78, 0.99) | ref | 1.01(0.94, 1.08) |
Adjusted model 1† | ref | 0.87(0.81, 0.93) | ref | 0.75(0.66, 0.85) | ref | 0.92(0.85, 0.99) |
Adjusted model 2† | ref | 0.97(0.91, 1.04) | ref | 0.81(0.71, 0.92) | ref | 1.05(0.97, 1.13) |
Adjusted model 3† | ref | 0.97(0.91, 1.04) | ref | 0.81(0.71, 0.92) | ref | 1.05(0.97, 1.13) |
- *Incidence rates per 1000 person years
- †Adjusted Model 1: adjusted for age, sex (only for total population), race, Townsend Deprivation Index, body mass index, smoking status, alcohol consumption, healthy diet score, vitamin or mineral supplementation, fish oil supplementation, comorbidities (hypertension, diabetes, high cholesterol, osteoarthritis, rheumatoid arthritis, and joint pain), and drug use (cholesterol lowering medication, anti-hypertensive drug, insulin, aspirin, ibuprofen, paracetamol, and diuretics); adjusted model 2: adjusted for the covariates in Model 1 and further adjusted for estimated glomerular filtration rate and urate; adjusted model 3: adjusted for the covariates in Model 2 and further adjusted for gout genetic risk score